Recorded Presentation from the New NCCN Guidelines for Pediatric Cancers: Management of Pediatric Aggressive Mature B-Cell Lymphoma
Clinicians who treat pediatric BL and DLBCL need to be informed about the recommendations in the new NCCN Guidelines for Pediatric Aggressive Mature B-Cell Lymphomas so that they can appropriately stratify patients into risk groups, plan initial therapy, and manage common supportive care issues. They also need information on recommended surveillance protocols and treatment of relapsed/refractory disease.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: Understanding the Molecular Heterogeneity of Diffuse Large B-Cell Lymphomas and the Place of Targeted Therapies in Treatment
New promising combinations of chemoimmunotherapy with antibody drug conjugates, and small molecule inhibitors may offer an alternative approach for patients with relapsed or refractory disease. Many of these new therapies are oral and will be managed by a multidisciplinary team.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Diffuse Large B-Cell Lymphoma: Optimizing Therapy for Relapsed/Refractory Disease
The advent of novel targeted therapies represents a major paradigm shift for management of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Outcomes of relapsed/refractory DLBCL differ based on the response to initial therapy, timing of relapse, and opportunity to undergo transplant. A multidisciplinary approach is required for appropriate patient selection and the management of acute toxicities to prevent fatal outcomes.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Updates on CAR T-cell Therapy for Relapsed/Refractory B-Cell Lymphomas
There is a clear need to educate clinicians regarding the special considerations for the administration of CAR T-cell therapy in appropriately selected patients, the unique spectrum of adverse events and effective management strategies.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Monthly Oncology Tumor Boards: Diagnosis and Management of Marginal Zone Lymphomas
Marginal zone lymphomas (MZLs) represent a clinical challenge due to their heterogeneity, and the relative rarity of individual subtypes has largely precluded the use of standard treatment approach across all subtypes. Educating clinicians about the biology of MZLs, novel therapeutic approaches, and special considerations will help them to develop an individualized treatment plan to optimize clinical outcomes.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Event date February 17, 2022